S 1637 · in committee · significant
MVP Act
- healthcare
What this bill does
- This bill allows drug manufacturers to use different pricing tiers under value-based purchasing arrangements where drug prices are tied to how well they work.
- It affects Medicaid and Medicare programs, manufacturers of high-cost drugs like gene therapies, and state health agencies.
- The Government Accountability Office must study the impacts, and CMS must issue guidance to states on implementation.
Generated by claude-haiku-4-5
Community Threads
Started by Cosponsor
- 01
How would tying drug prices to real-world effectiveness rather than development costs change which treatments become affordable for Medicaid and Medicare patients?
- 02
What risks exist that manufacturers could manipulate effectiveness data to justify higher prices under value-based pricing arrangements?
- 03
Which states have the capacity to negotiate and monitor these tiered pricing agreements, and how would less-resourced states be supported?
Cosponsor writes these to seed civic discussion — they aren't user posts. Sign in to reply.
Sponsor · R-OK
Markwayne Mullin
Citizen cosponsors
0
In Congress
2/ 100
Senators cosponsoring
Introduced 2025-05-07
Joining the bill
Legislative timeline
2025-05-07 · senate · IntroReferral
Read twice and referred to the Committee on Finance.
2025-05-07 · IntroReferral
Introduced in Senate
Citizen comments
Sign in to comment on this bill.
No comments yet — be the first.